Tyme Technologies And Eagle Pharmaceuticals Announce Collaboration To Advance Oral SM-88 For Treatment Of Patients With Cancer; Tyme Entitled To Receive Total Of $40M In The Form Of Upfront Payment And Milestones
Benzinga Newsdesk